Last Updated: November 19, 2026

Details for Patent: 10,683,302

« Back to Dashboard


Which drugs does patent 10,683,302 protect, and when does it expire?

Patent 10,683,302 protects REVUFORJ and is included in one NDA.

This patent has forty-two patent family members in twenty-two countries.

Summary for Patent: 10,683,302
Title:Inhibitors of the menin-MLL interaction
Abstract:The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.
Inventor(s):Salvacion Cacatian, David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Lanqi Jia, Stephen D. Lotesta, Andrew Marcus, Angel MORALES-RAMOS, Suresh B. Singh, Shankar Venkatraman, Jing Yuan, Yajun ZHENG, Linghang Zhuang, Stephan D. PARENT, Travis L. Houston
Assignee: Vitae Pharmaceuticals LLC
Application Number:US16/308,739
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 10,683,302

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Syndax REVUFORJ revumenib citrate TABLET;ORAL 218944-001 Nov 15, 2024 RX Yes No 10,683,302 ⤷  Start Trial Y Y ⤷  Start Trial
Syndax REVUFORJ revumenib citrate TABLET;ORAL 218944-002 Nov 15, 2024 RX Yes No 10,683,302 ⤷  Start Trial Y Y ⤷  Start Trial
Syndax REVUFORJ revumenib citrate TABLET;ORAL 218944-003 Nov 15, 2024 RX Yes Yes 10,683,302 ⤷  Start Trial Y Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,683,302

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2017278950 ⤷  Start Trial
Australia 2021258089 ⤷  Start Trial
Australia 2024202700 ⤷  Start Trial
Brazil 112018075260 ⤷  Start Trial
Brazil 122024002146 ⤷  Start Trial
Canada 3024180 ⤷  Start Trial
Canada 3297462 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.